Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Grifols S.A. (GRFS)

Grifols S.A. (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Grifols Procleix Panther System With Automation Ready Technology (ART) Receives CE-mark

- ART enables greater workflow efficiency and lean sample management, supporting laboratories' path towards total automation

GRFS : 20.68 (+1.42%)
GRF : 8.19 (+0.12%)
Grifols presents additional encouraging Alzheimer's trial results at AAIC

The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial for the treatment of Alzheimer's...

GRF : 8.19 (+0.12%)
GRFS : 20.68 (+1.42%)
Company News for Jul 8, 2019

Companies In The News Are: OASM,GOL,GRFS,DELL

GOL : 17.19 (+0.47%)
DELL : 50.37 (-0.34%)
GRFS : 20.68 (+1.42%)
OASM : 1.55 (+1.97%)
Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies

Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S....

GRF : 8.19 (+0.12%)
GRFS : 20.68 (+1.42%)
Grifols Selected to Build Its First Intravenous Solutions Manufacturing Line in Africa

Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced it has been selected by Soludia Maghreb,...

GRF : 8.19 (+0.12%)
GRFS : 20.68 (+1.42%)
GRFS or ORINY: Which Is the Better Value Stock Right Now?

GRFS vs. ORINY: Which Stock Is the Better Value Option?

GRFS : 20.68 (+1.42%)
ORINY : 18.7250 (unch)
Grifols Announces the Opening of its new Plasma Donor Center in Hinesville, Georgia

Grifols is pleased to announce the opening of a new Biotest plasma donor center located at 108 West Hendry Street, Hinesville, Georgia. The 11,000 square foot state-of-the-art facility officially opened...

GRF : 8.19 (+0.12%)
GRFS : 20.68 (+1.42%)
Grifols donations of blood clotting factor helping people with hemophilia globally

Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with...

GRF : 8.19 (+0.12%)
GRFS : 20.68 (+1.42%)
Immunoglobulins Market to Touch US$ 20,757.1 Mn by 2026, Advancements in Research and Development of Plasma Synthesis to Boost Prospects - TMR

Transparency Market Research (TMR) points entry of new players in the global immunoglobulins market. This is due to a significant boost in number of FDA approvals for immunoglobulins drugs and vaccinations....

GRFS : 20.68 (+1.42%)
New Research: Key Drivers of Growth for Grifols, S.A, LG Display Co., Summit Midstream Partners, LP, Mammoth Energy Services, Reading International, and Great Ajax -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Grifols, S.A. (NASDAQ:GRFS),...

RDIB : 24.22 (-0.12%)
GRFS : 20.68 (+1.42%)
LPL : 6.06 (-0.16%)
SMLP : 4.54 (unch)
TUSK : 2.03 (-0.98%)
RDI : 11.70 (+2.72%)
AJX : 15.79 (+0.83%)
Grifols 2018 Annual Report on Form 20-F Filed With the SEC on April 5, 2019

Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2018 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April...

GRF : 8.19 (+0.12%)
GRFS : 20.68 (+1.42%)
Grifols Announces the Opening of its new Plasma Donor Center in Russellville, AR

Grifols is pleased to announce the opening of a new Biotest plasma donor center located at 1105 W Main Street, Russellville, Arkansas. The 15,000 square foot state-of-the-art facility officially opened...

GRF : 8.19 (+0.12%)
GRFS : 20.68 (+1.42%)
Grifols PharmacyKeeper Receives KLAS Category Leader Award for Third Consecutive Year

Grifols has earned the honor of 2019 Category Leader in IV Workflow Management in the 2019 Best in KLAS: Software & Services report for its PharmacyKeeper Verification product.

WORK : 24.00 (+1.52%)
GRF : 8.19 (+0.12%)
GRFS : 20.68 (+1.42%)
Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System

Grifols, a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that the U.S. Food and Drug Administration (FDA) approved...

GRF : 8.19 (+0.12%)
GRFS : 20.68 (+1.42%)
Crypto market forecast: 10th June

The crypto market continued its difficult start to the month of June with most large cap assets correcting strongly over the last 7 days. Many analysts believe more corrections are incoming based on both...

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +4.89 , AIZ +0.49 , SBAC +7.10 , SO -0.03 , WELL +0.16
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar